Bulgaria should remove clawback taxes for generics and biosimilars, avoid external reference-pricing mechanisms, adopt measures to drive up generic prescribing and adopt a “dynamic” biosimilars policy to encourage uptake, European off-patent industry association Medicines for Europe has urged. The industry body has also called on the new European Commission to offer the country its support in these areas.
Action must be taken in Bulgaria to bolster the country’s generics and biosimilars market, according to European off-patent industry association Medicines for Europe.
In particular, the association has called for Bulgaria to remove clawback taxes for generics and biosimilars; avoid external reference-pricing mechanisms;...